

**Multidisciplinary Orthopedic Oncology Tumor Board Conference**  
**Provided by Rutgers New Jersey Medical School, Department of Radiology**

***Interesting Cases on 9/30/2021***  
**150 Bergen St., E-349, Newark, NJ**  
**9/30/2021**  
**3:30PM to 4:30PM**



**Judah Goldschmiedt, MD**  
Assistant Professor, Rutgers New Jersey Medical School

**Objectives**

At the conclusion of this activity, participants should be better able to:

- Identify the common presentation of varied orthopedic oncologic diseases.
- Recognize the varied imaging modalities available to direct diagnosis and treatment, as well as limitations of each.
- Review the optimal and adjuvant roles of medical oncology, radiation oncology and orthopedic surgery take in treatment of these diseases.

**Target Audience**

This activity is designed for radiologists, pathologists, surgeons, internists, physician assistants, medical students and radiology/orthopedic residents

**Accreditation**



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

**Physicians:** Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Declarations**

Judah Goldschmiedt, MD has no relevant financial relationships with ineligible companies to disclose.

Speakers are required to disclose discussion of off-label/investigational uses of commercial products/devices in their presentation. These disclosures will be made to the audience at the time of the activity.

**Planning Committee:**

Drs. Goldschmiedt (Content Reviewer) Beebe, Aisner, and Wenokor have no relevant financial relationships with ineligible companies to disclose.